ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 171 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,243,515 | -74.7% | 782,085 | -0.8% | 0.00% | -77.8% |
| Q4 2022 | $4,911,520 | +37.7% | 788,366 | +520.0% | 0.02% | +63.6% |
| Q1 2021 | $3,566,000 | +51.9% | 127,146 | +40.8% | 0.01% | +57.1% |
| Q4 2020 | $2,347,000 | +243.1% | 90,272 | +390.7% | 0.01% | +250.0% |
| Q3 2020 | $684,000 | -64.1% | 18,395 | -50.5% | 0.00% | -50.0% |
| Q2 2020 | $1,906,000 | +71.4% | 37,162 | +5.4% | 0.00% | +33.3% |
| Q1 2020 | $1,112,000 | -88.7% | 35,256 | -78.6% | 0.00% | -85.0% |
| Q4 2019 | $9,810,000 | +2785.3% | 164,520 | +3400.4% | 0.02% | +1900.0% |
| Q1 2018 | $340,000 | -87.8% | 4,700 | -96.0% | 0.00% | -90.9% |
| Q3 2015 | $2,777,000 | -56.5% | 117,703 | +50.7% | 0.01% | -57.7% |
| Q2 2015 | $6,385,000 | -11.7% | 78,091 | 0.0% | 0.03% | -13.3% |
| Q1 2015 | $7,231,000 | +101.9% | 78,091 | -11.8% | 0.03% | +114.3% |
| Q4 2014 | $3,581,000 | – | 88,546 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |